



BACKGROUNDER

INFLUENZA VACCINE MANUFACTURING AT SANOFI

Sanofi Vaccines Global Manufacturing Scale & Reach

Sanofi is a global leader in vaccine manufacturing, with more than 250 million doses manufactured and distributed globally each year to protect people around the world. Sanofi operates vaccine production sites in France, Canada, United States, Mexico, Argentina, and China.

Industry Leadership

Sanofi is the **world's #1 producer of influenza vaccines**, demonstrating decades of expertise in vaccine development and manufacturing.

Commitment to Quality

70% of production time is dedicated to quality testing, ensuring every vaccine meets the highest safety and efficacy standards. Vaccines undergo extensive testing before regulatory approval and are continuously monitored through Sanofi's pharmacovigilance system once in use.

THE CHARLES BEST INFLUENZA VACCINE FACILITY, PART OF THE PANDEMIC READINESS PROJECT: BUILDING OUR FUTURE

- The Charles Best Building is a state-of-the-art facility for vaccine production located within Sanofi's Toronto Campus – the largest biopharma manufacturing site in Canada.
- **Products:** The facility will provide antigen for Sanofi's Fluzone® High-Dose influenza vaccine, increasing supply availability in Canada and other countries around the world. In addition, this new manufacturing facility will strategically grow Canada's bio-manufacturing sector and install industrial scale capacity to strengthen Canada's preparedness for future pandemics.
- **Financial investment:** The \$925 million investment, [announced in 2021](#), represents a landmark partnership between Sanofi and Canadian governments, demonstrating a shared commitment to vaccination and public health. These investments include \$415M in support from the Federal Government via the Strategic Innovation Fund (SIF), and \$55M from the Government of Ontario.



- **Job creation:** The development of this vaccine production chain is creating approximately 300 highly skilled jobs at Sanofi, with roles in several areas including production, quality, manufacturing science and the trades.
- **End-to-end Manufacturing:** The building is the anchor facility in an end-to-end influenza vaccine production chain, which spans drug substance and also formulation, filling, inspection, and packaging (FFIP). Together, these facilities represent the single largest investment ever in Canadian biomanufacturing, and one of the one of the largest-ever investments by Sanofi in a single building.
- **Building Footprint:** 18,099m², with an additional 6,283 m² in the broader FFIP footprint, these buildings will be the largest end-to-end vaccine production facility in Canada.
- **Digital Systems:** The facility leverages an integrated digital ecosystem providing real-time process control, batch execution, and operational analytics; these digital, AI powered insights increase manufacturing efficiency, process robustness and overall high-quality production.
- **Facility background:** The facility is named after Charles Best, who worked alongside Frederick Banting in the pivotal experiments that led to insulin's discovery in 1921–1922. After the discovery, Best took charge of scaling up insulin production at Connaught Laboratories — the University of Toronto-affiliated institution that is the historical predecessor of today's Sanofi Toronto Campus. The building stands on the grounds of our former insulin facility and honours our heritage.